Can adjuvant pembrolizumab benefit selected high-risk patients with renal cell carcinoma?
For patients with high-risk renal cell carcinoma (RCC) who have had surgery, the risk of cancer returning is significant. Adjuvant therapy (treatment after surgery) aims to lower that risk. Pembrolizumab, an immune checkpoint inhibitor, has shown benefit in carefully selected high-risk patients, including those with M1 no evidence of disease after metastasectomy. However, not all patients benefit, and the decision depends on individual risk factors.
What the research says
The KEYNOTE-564 trial is the landmark study showing that adjuvant pembrolizumab improves disease-free survival and overall survival in selected high-risk RCC patients after nephrectomy or metastasectomy 791011. This benefit was seen in patients with clear-cell RCC at increased risk of recurrence, including those with M1 no evidence of disease 79. Based on these results, pembrolizumab received FDA and EMA approval for this indication 9. However, other immune checkpoint inhibitors tested in similar settings did not show consistent benefit, indicating that the effect is not class-wide and depends on patient selection and disease biology 710. Accurate risk assessment using tools like the UCLA Integrated Staging System or Leibovich score is critical to identify who is most likely to benefit 11. Ongoing research focuses on biomarkers, such as liquid biopsies, to further refine patient selection 11.
What to ask your doctor
- Based on my pathology and risk score (e.g., Leibovich or UCLA Integrated Staging System), am I considered high-risk for recurrence?
- What is the evidence from the KEYNOTE-564 trial for adjuvant pembrolizumab in my specific situation?
- What are the potential side effects of adjuvant pembrolizumab, and how are they managed?
- How long would I need to take adjuvant pembrolizumab, and what does follow-up monitoring involve?
- Are there any ongoing clinical trials or newer biomarkers (like liquid biopsies) that might help decide if this treatment is right for me?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.